Is Seroquel (Quetiapine) Safe with Ketamine?

Quetiapine (Seroquel) is one of the more clinically interesting medications to discuss in the context of at-home ketamine therapy because the same drug serves so many different patient populations at such different doses. The Seroquel 600 mg/day patient on the medication for schizophrenia is in a fundamentally different clinical conversation than the Seroquel 25 mg-at-bedtime patient using it off-label for insomnia. The verdict (case-by-case) reflects that variability; the underlying combination with ketamine is safe across the dose range, and continuing quetiapine throughout the ketamine course is the standard approach in every case.

The dose-and-indication picture

Quetiapine has FDA approval for schizophrenia, acute mania in bipolar I disorder, bipolar depression, bipolar maintenance, and adjunctive treatment of MDD (Seroquel XR specifically). Off-label use for insomnia is extremely common at low doses (25-100 mg at bedtime), accounting for a substantial fraction of quetiapine prescriptions in primary care. Each of these indications shapes the ketamine intake conversation slightly:

Schizophrenia or schizoaffective disorder (typically 300-800 mg/day): The primary clinical question is whether at-home ketamine is appropriate for this patient population at all. Tovani's general approach is that schizophrenia is a more complicated psychiatric picture than at-home unmonitored ketamine is designed for, and we coordinate carefully with treating psychiatry before proceeding. For patients with well-controlled schizophrenia on stable quetiapine who have a clear separate depression component, ketamine may be appropriate with strong care coordination; for active psychotic symptoms or unstable schizophrenia, it is not.

Bipolar I or II depression (typically 300-400 mg/day, often Seroquel XR): The conversation looks similar to bipolar depression on lithium or lamotrigine. Continuing the mood stabilizer (quetiapine in this case) is the right move and meaningfully reduces manic-switch risk during ketamine therapy. The Fancy et al. 2023 systematic review put the pooled manic/hypomanic switch rate at approximately 2% across studies and noted it's lower when patients remain on a mood stabilizer, which atypical antipsychotics like quetiapine are.

MDD augmentation (typically 150-300 mg Seroquel XR): This is the FDA-approved adjunctive indication for major depression that hasn't fully responded to an antidepressant alone. These patients are exactly who at-home ketamine is designed for, and the conversation is essentially the same as any TRD patient with quetiapine as one of their concurrent medications.

Off-label low-dose insomnia (25-100 mg at bedtime): A common pattern in primary care and outpatient psychiatry. At these doses quetiapine is functioning mostly as a sleep aid through its antihistamine and sedating profile rather than as an antipsychotic per se. The ketamine intake conversation is straightforward: continue your bedtime dose normally.

What the published evidence shows

The direct evidence on quetiapine plus ketamine specifically is thin. The Veraart 2021 systematic review of ketamine pharmacodynamic interactions (PMID 34170315) reviewed several antipsychotics (haloperidol, risperidone, clozapine, olanzapine) but did not directly cover quetiapine. For the antipsychotics that were reviewed:

No case reports of adverse events from combining ketamine with antipsychotics were identified.

For risperidone specifically (probably the closest pharmacologic analog among atypicals reviewed), anecdotal reports at 1-4 mg/day were that risperidone did not attenuate ketamine's antidepressant benefits.

Haloperidol pretreatment in research settings modestly reduced some acute cognitive effects of ketamine but did not block its psychotomimetic effects or its antidepressant action.

By extension, quetiapine at typical doses is likely safe to combine with ketamine without meaningfully blunting either the dissociative experience or the antidepressant response. Our own clinical experience supports this; patients on quetiapine respond to ketamine on similar trajectories to patients on no antipsychotic, with the bipolar context (for those whose quetiapine is for bipolar) being the more relevant intake conversation.

The Alnefeesi 2022 real-world meta-analysis (PMID 35688035) pooled 2,665 TRD patients across 79 studies; atypical antipsychotic augmentation including quetiapine is common in TRD populations and was included throughout. The 45% pooled response rate and 30% remission rate reflect this mixed population.

No quetiapine-specific case reports of serotonin syndrome or other adverse outcomes from at-home ketamine combination exist in the published literature.

The sedation question

Quetiapine is notably sedating, especially at lower doses where the H1 antihistamine effect dominates. Patients on bedtime quetiapine reliably report sedation that resolves by morning; patients on higher daytime doses (for bipolar or psychotic indications) often have ongoing baseline sedation that's part of why they're on the medication.

For ketamine session day, the sedation stacking is a small clinical consideration but generally not a major one. If you take quetiapine in the evening before a daytime session, the medication is well-cleared by session time and no adjustment is needed. If you take quetiapine multiple times daily (for bipolar or schizophrenia indications), we discuss whether the morning dose is necessary or whether shifting it to after the session is reasonable.

For low-dose insomnia use specifically, some patients prefer to skip the bedtime dose the night before an early-morning session to feel maximally clear-headed for the experience; others find it makes no difference. We discuss preferences at intake but don't insist on any specific pattern.

The cardiovascular and metabolic notes

Quetiapine at higher doses (300+ mg/day) carries the atypical antipsychotic class effects: weight gain, dyslipidemia, hyperglycemia, and modest QT-interval prolongation. These are ongoing monitoring concerns for the treating psychiatrist independent of ketamine; they don't directly change ketamine eligibility.

For patients on high-dose quetiapine with cardiovascular history, we ask for recent ECG documentation (within 6-12 months) confirming acceptable QTc, similar to what we do for high-dose Celexa or high-dose methadone patients. Ketamine itself has minor cardiovascular effects but doesn't specifically prolong QT, so the combination concern is small at therapeutic ketamine doses.

What we do at intake

When a patient is on quetiapine, our intake process for ketamine includes:

The dose and frequency. Critical for shaping the conversation; low-dose for sleep is a very different picture from high-dose for primary psychiatric indication.

The indication. Schizophrenia, schizoaffective, bipolar I, bipolar II, MDD augmentation, insomnia, or other. Each indication has a slightly different intake conversation.

How long you've been on the current dose. Stable for at least 6-8 weeks is the most common picture.

Your relationship with the prescribing physician. For non-MDD indications (schizophrenia, bipolar) we ask for a release of information to coordinate care.

Recent mood-episode history (if bipolar) or psychotic symptoms (if schizophrenia or schizoaffective). Recent breakthroughs in either category are flags for additional conversation.

Cardiovascular history and baseline QTc if available. Especially relevant for high-dose patients.

Tapering: a separate conversation

Some patients ask whether ketamine could be a bridge to coming off quetiapine. The answer depends entirely on the indication. For bedtime-insomnia quetiapine, some patients find that ketamine treating the underlying depression resolves the insomnia and they can taper the low-dose Seroquel; this is a reasonable and often-successful trajectory. For quetiapine treating schizophrenia or bipolar disorder, it is not a candidate for ketamine-driven tapering; those indications require sustained antipsychotic or mood-stabilizer therapy, and ketamine treats a different clinical problem.

Any tapering decision belongs entirely between you and your prescribing physician on its own clinical merits. We do not tie ketamine eligibility to tapering and do not push tapering as a goal.

Bottom line

Quetiapine combined with at-home ketamine is pharmacologically safe; the case-by-case verdict reflects the wide range of clinical contexts the same medication serves. Schizophrenia and schizoaffective indications get the most detailed intake conversation and may require closer-monitored care; bipolar depression on quetiapine is similar to lithium or lamotrigine bipolar conversations; MDD augmentation and off-label insomnia use are straightforward. Standard practice across all indications is to continue quetiapine throughout the ketamine course, with intake calibrated to the underlying clinical picture.